DEFINIUM THERAPEUTICS, INC.

NASDAQ: DFTX (Definium Therapeutics, Inc.)

最近更新时间: 7小时之前

28.34

-1.14 (-3.87%)

前收盘价格 29.48
成交量 3,238,037
平均成交量 (3个月) 2,163,526
市值 4,837,210,112
股市价格/股市净资产 (P/B) 4.54
52周波幅
10.53 (-62%) — 49.70 (75%)
利润日期 5 Nov 2026

AIStockmoo 评分

0.0
资本回报低于资本成本。资本回报上升。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
财务健康 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈上升趋势。股价远低于52周高点。 参考
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
持仓情绪 参考 NA
机构在最新13F申报中净+8.02%的股份:216家增持,167家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-2.3%,回补天数5.8天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
每股盈利大多下降。近年曾亏损。 参考
低于中期趋势线。 参考
股价接近其52周平均水平。5年来下跌。 参考
短期动能下降。 参考
股价接近阻力位。支撑与阻力水平趋降。 参考
最终评分 -0.01
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Definium Therapeutics, Inc. 混合的 -

相关股票

股票 市值 DY P/E(TTM) P/B 评分
DFTX 5 B - - 4.54 0.0
SYRE 9 B - - 10.08 1.1
MDGL 9 B - - 14.74 -0.4
CORT 7 B - 47.78 8.89 -1.5
FOLD 5 B - - - 0.0
TARS 4 B - - 36.00 0.6

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth

所有权

姓名 日期 持有股份
Capital World Investors 30 Sep 2026 8,255,584
Octagon Capital Advisors Lp 30 Sep 2026 2,511,000
Alliancebernstein L.P. 30 Sep 2026 1,938,303

该时间范围内无数据。

机构

机构持股比例: 92.20%

持仓变动 机构数 股数
增持 216 29,390,198
减持 167 18,014,338
新建仓 70 8,825,116
清仓 70 9,208,628

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 9,613,993 5.8
15 Oct 2026 10,044,279 4.9
30 Sep 2026 11,344,959 4.9
15 Sep 2026 11,785,195 5.2
31 Aug 2026 9,836,400 5.6
14 Aug 2026 8,969,420 3.4

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

6 正面 0 负面 6 中性
日期 类型 细节
20 Nov 2026 Yahoo Finance Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
Definium Therapeutics (NASDAQ:DFTX) expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset. CEO Rob Barrow sai…
16 Nov 2026 Yahoo Finance Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight.
16 Nov 2026 Yahoo Finance Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms Posted Record Cannabis Revenue as International Exports Surged 75% Auxly Cannabis Delivered Record Q3 Revenue as Adjusted EBITDA Climbed 29% Key Takeaways; Psychedelic Sector Definium Therapeutics Reported Strong Q3 Results as DT120 Advanced Towards…
12 Nov 2026 Yahoo Finance Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
Definium Therapeutics has seen its stock price move sharply in recent years, and the surge now raises a straightforward question for investors who care about balance sheet strength. Is the current market value still grounded in Definium Therapeutics' book value, or has the share price pulled…
11 Nov 2026 Yahoo Finance How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
Definium Therapeutics reported positive Phase 3 data for DT120 in generalized anxiety disorder and major depressive disorder, alongside plans to seek FDA approval after multiple pivotal studies. Recent earnings showed ongoing net losses tied to development spend. The most distinctive angle is that…
11 Nov 2026 Yahoo Finance Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Definium Therapeutics (DFTX) is back in focus after reporting third quarter results that showed a reduced quarterly net loss alongside a much larger cumulative loss for the first nine months of 2026. Definium Therapeutics has ridden a sharp re-rating over 2026, with the share price delivering a…
11 Nov 2026 Yahoo Finance Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s…
10 Nov 2026 Yahoo Finance Definium Therapeutics Inc (DFTX) (Q3 2026) Earnings Call Highlights: $1. ...
Definium Therapeutics Inc (DFTX) pairs a cash runway into 2030 with two FDA breakthrough therapy designations for DT120 and a planned first-half 2027 NDA filing, even as R&D and G&A spending climb.
09 Nov 2026 Yahoo Finance Definium (DFTX) Q3 2026 Earnings Call Transcript
Phase 3 wins set up a 2027 filing and a commercial push.
09 Nov 2026 Yahoo Finance What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s…
09 Nov 2026 Yahoo Finance Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported…
09 Nov 2026 Yahoo Finance Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of…
04 Nov 2026 Yahoo Finance Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK, November 04, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four…
03 Nov 2026 Yahoo Finance Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that…
29 Oct 2026 Yahoo Finance Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK, October 29, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30…
19 Oct 2026 Yahoo Finance Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Definium Therapeutics has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$32.97 level is supported by the book value on its balance sheet. With such a strong price story already on the table, investors are asking how much of that journey is…
30 Sep 2026 Yahoo Finance Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward…
显示更多

技术形态 中期

趋势排列
斜率
入场位置
成交量
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。
最近支撑: 25.76 – 26.74 · 中等
最近阻力: 29.68 – 30.66 · 中等

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票